…3 Years Later Increased risk for adverse cardiovascular outcomes and invasive breast cancer — and reduced risk for fractures and colorectal cancer — did not persist after women discontinued HT. In the summer of 2002, the Women’s Health Initiative (WHI) randomized trial of estrogen plus progestin was stopped after the WHI writing group concluded that [...]
Main Outcome: Measures Semi-annual monitoring and outcomes ascertainment continued per trial protocol. The primary end points were coronary heart disease and invasive breast cancer. A global index summarizing the balance of risks and benefits included the 2 primary end points plus stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, and death due to other causes.
The Women’s Health Initiative (WHI) Trial Team Gerardo Heiss, MD; Robert Wallace, MD; Garnet L. Anderson, PhD; Aaron Aragaki, MS; Shirley A. A. Beresford, PhD; Robert Brzyski, MD; Rowan T. Chlebowski, MD; Margery Gass, MD; Andrea LaCroix, PhD; JoAnn E. Manson, MD; Ross L. Prentice, PhD; Jacques Rossouw, MD; Marcia L. Stefanick, PhD; for the [...]
While Wyeth Wrings Profits From Womens BodiesHere’s some news that will make us all depressed – Wyeth has won FDA approval for its new antidepressant Pristiq. Yes, the same FDA who has just told us “bioidentical hormones” don’t exist, the same FDA who has told compounding pharmacists to stop using Estriol, the mildest of estrogens [...]
© 2002- An Inconvenient Woman. Site design and construction by Pleiades Publishing Services, Co.
Powered by Wordpress and based on the template design MyJournal Hypereal by 
BlogoSquare
